MYFORTIC 180mg Novartis tablets for patients with genetic kidneys (12 blisters x 10 tablets)

Dosage form Box of 12 blisters x 10 tablets
Specifications Mycophenolic acid

Ingredient

Composition information	Content
Mycophenolic acid	180mg

Uses

Indications

MyFortic medicine 180mg is indicated in the following cases:

Used in combination with ciclosporin micro -form and corticosteroids to prevent acute pieces in patients with genetic kidney transplantation.

pharmacokinetics

No data.

Before taking MYFORTIC 180mg Novartis tablets for patients with genetic kidneys (12 blisters x 10 tablets)

How to use

Myfortic 180mg can be taken or not with food.

To retain the integrity of the intestinal coating, the Myfortic 180mg tablet is not crushed. When grinding myfortic tablets, inhaling the dough or letting the dough come in direct contact with the skin or mucous membranes. This is due to the monster effect of Mycophenolate.

Dosage

The recommended dose is 720 mg (4 tablets of myfortic insoluble in the stomach type 180 mg or 2 tablets 360 mg), 2 times a day (daily dose 1,440 mg). In patients using Mycophenolate Mofetil (mmf) 2 g, the treatment can be replaced with 720 mg of Myfortic twice a day (daily dose 1,440 mg).

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when overdose? This is largely due to the very high plasma protein of MPA, 97%. By interfering with the circulation through the liver of MPa, bile -isolated substances, such as cholestyramine, can reduce the exposure of the whole body.

What to do when forgetting 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.

Side Effects

When using myfortic drug 180mg, you may experience unwanted effects (ADR).

Common, ADR> 1/100

Infections of upper respiratory tract, pneumonia.

Anemia, thrombocytopenia.

Hemorrhage, hypokalemia.

Dizziness, headache.

Low blood pressure.

cough, shortness of breath.

Abdominal obstacles, abdominal pain, constipation, indigestion, flatulence, gastritis, nausea, vomiting.

Uncommon, 1/1000

Infection with wounds, bone infections, osteomyelitis.

Anorexia, hyperlipidemia, diabetes, hypercholesterolemia, blood phosphorus.

Illusion awareness, insomnia.

Conjunctivitis, blurred vision.

tachycardia, external ventricular.

Instructions on how to handle ADR

When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Myfortic medicine 180mg contraindicated in the following cases:

Patients with hypersensitivity to sodium mycophenolate, mycophenolic acid or mycophenolate mofetil or any excipients.

Women have the ability to give birth (WOCBP), who do not use highly effective contraception.

Pregnant women unless there is no appropriate alternative treatment to prevent transplantation.

Women who are breastfeeding.

Precautions when used

Patients using Myfortic 180mg in the treatment regimen, there are many risks of developing lymphoma and other malignant tumors, especially in the skin. According to the general advice to minimize the risk of skin cancer, it is advisable to limit exposure to sunlight and UV rays by wearing protective clothes and using sunscreen with high protection index.

Patients using myfortic 180mg should be instructed immediately to report any evidence of infection, unexpectedly bruising, bleeding or any other symptoms of bone marrow failure.

Patients using Myfortic 180mg, there are many risks of opportunistic infections, death infections and hemorrhage. These infections should be considered by a doctor in the diagnosis of distinguished in patients with immunosuppressive patients with renal function or impaired neurological symptoms.

There have been reports on hypoglycemia related to recurrent infections in patients using Myfortic in combination with other immunosuppressive drugs. Patients treated with recurrent infections should be measured in serum immune globulin.

There has been a report on bronchodilators in patients using Myfortic in combination with other immunosuppressive drugs. The conversion of MPA derivatives to another immunosuppressant, resulting in improving respiratory symptoms.

The reaction of hepatitis B (HBV) or hepatitis C (HCV) has been reported in patients treated with immunosuppressive drugs, including Mycophenolic Acid (MPA) derivatives (MPA) MyFortic and Mycophenolate Mofetil (MMF). Monitoring infected patients for clinical signs and testing of HBV or HCV infection is recommended.

Single cases of red blood cells (PRCA) have been reported in patients treated with MPA derivatives in combination with other immunosuppressive drugs. Prca can be resolved by reducing the dose or stopping treatment and is performed under appropriate monitoring in people who receive organ transplantation to minimize the risk of transplantation.

Patients using Myfortic should be monitored with blood disorders, which may be related to MPA itself, use the medication simultaneously, infected with viruses or some combined causes. Patients who use Myfortic must have a full blood recipe for the first month, twice a month for the second and third month of treatment, then monthly until the first year.

Because MPa's derivatives are associated with the increase in the proportion of the gastrointestinal side effects, including cases of ulcer and bleeding and perforation of the gastrointestinal tract regularly, carefully when taking Myfortic in patients with serious digestive diseases.

Myfortic is an IMPDH inhibitor (Inosine monophosphate dehydrogenase). Therefore, this drug should be avoided in patients with hypoxanthine-guanine phosphoribosyl-gsferase (HGPRT) due to rare genetics such as lesch-nyman and kelley-echley-ligmiller syndrome.

Using drugs for women during pregnancy and lactation

Pregnancy

Myfortic 180mg is contraindicated during pregnancy unless there is no appropriate replacement treatment to prevent grafting.

Patients with fertility must be aware of the risk of miscarriage and increased birth defects at the beginning of treatment and must be advised on planning and pregnancy prevention.

Breastfeeding period

mpa is excreted through breast milk. It is still not known whether Myfortic 180mg is excreted through breast milk or not. Due to the possibility of serious harmful reactions to MPA in breastfeeding, Myfortic 180mg contraindicated in breastfeeding women.

The ability to drive and operate machinery

There is no research on the ability to drive and use machines. Active mechanism and pharmacological force and harmful reactions are reported that the effect is hard to occur.

Medicinal interaction

aciclovir and ganciclovir

The ability to cause marrow failure in patients using both Myfortic and Aciclovir or Ganciclovir has not been studied, may be the result of the competition in the excretory line in the renal tubules.

antacids containing magnesium and aluminum

MPa AUC and C Max have been shown to be reduced by 37% and 25%, when taking a single dose of antacids containing magnesium-magners used simultaneously with Myfortic 180mg. The use of antacids containing magnesium daily with myfortic is not recommended due to the ability to reduce exposure to mycophenolic acid and reduce efficiency.

Proton pump inhibitors

In healthy volunteers, there is no change in the pharmacokinetics of MPA after simultaneous use of Myfortic and Pantoprazole at a dose of 40 mg x 2 times / day for 4 days earlier.

Oral contraceptives

Studies on interaction between MMF and birth control pills show that there is no interaction. With the metabolic characteristics of MPA, there will be no interactions that occur for Myfortic and birth control pills.

cholestyramine and bile acid bonds

Be cautious when using the medications or therapy that can be linked to bile acid, such as isolation of bile acid or activated carbon oral, because it has the ability to reduce MPA exposure and thus reduce the effectiveness of MyFortic 180mg.

ciclosporin

When used simultaneously with Mycophenolate Mofetil, Ciclosporin is known to reduce the exposure of MPA. When used simultaneously with Myfortic, Ciclosporin can also reduce the concentration of MPA.

Power -reducing lifestyle

Do not live a living vaccine for patients with impaired immune response. The reaction of antibodies for other vaccines may be reduced.

Other drugs

It is recommended not to simultaneously use myfortic with azathioprine because the use of these drugs has not been evaluated at the same time.

Concomitance the use of myfortic and drugs that hinder the intestinal circulation, such as cholestyramine or activated carbon, can lead to exposure to the whole body mpa under treatment and reduce effectiveness.

Storage

Leave the medicine in a dry, airy place, avoid light, temperatures below 30 ° C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.